Williams Jones & Associates’s Novo Nordisk NVO Stock Holding History

Williams Jones & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-12,700	Closed	-$369K	–	379
2015 Q4	$369K	Buy	12,700 +200	+2%	+$5.54K	0.02%	246
2015 Q3	$339K	Buy	12,500 +400	+3%	+$11.3K	0.02%	265
2015 Q2	$331K	Hold	12,100	–	–	0.01%	291
2015 Q1	$323K	Sell	12,100 -3,400	-22%	-$78.3K	0.01%	297
2014 Q4	$328K	Hold	15,500	–	–	0.01%	295
2014 Q3	$369K	Hold	15,500	–	–	0.02%	240
2014 Q2	$358K	Sell	15,500 -19,500	-56%	-$431K	0.02%	242
2014 Q1	$799K	Buy	35,000 +15,500	+79%	+$330K	0.02%	256
2013 Q4	$360K	Buy	+19,500	New	+$340K	0.02%	217

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Williams Jones & Associates's NVO Position: Q1 2016 in Review

Williams Jones & Associates sold out of Novo Nordisk (NVO) in Q1 2016, closing a stake of 12,700 shares — an estimated $369K sold.

Williams Jones & Associates first reported a position in NVO in Q4 2013 and held it in 9 quarters. The position peaked at $799K in Q1 2014. 535 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

Williams Jones & Associates reported no remaining Novo Nordisk position as of Q1 2016 after selling out during the quarter.
Williams Jones & Associates sold 12,700 Novo Nordisk shares in Q1 2016, an estimated $369K.
Williams Jones & Associates first reported a position in Novo Nordisk in Q4 2013 and held it in 9 quarters.
Williams Jones & Associates's Novo Nordisk position peaked at $799K in Q1 2014.
535 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Williams Jones & Associates's 13F filing for Q1 2016, filed 16 May 2016.